Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 12,674	$ 10,299
Marketable securities	16,487	32,754
Prepaid and other current assets	1,083	1,053
Total current assets	30,244	44,106
Property and equipment, net	115	165
Other assets	1,312	309
Total assets	31,671	44,580
Liabilities
Accounts payable	844	762
Accrued liabilities	5,135	4,857
Total current liabilities	5,979	5,619
Other long-term liabilities	710	1,507
Total liabilities	6,689	7,126
Commitments and Contingencies
Stockholders' Equity
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2019 and December 31, 2018, respectively	0	0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 10,411,010 and 9,865,735 shares at September 30, 2019 and December 31, 2018, respectively	10	10
Additional paid-in capital	438,388	436,433
Treasury stock, at cost; 11,080 shares at September 30, 2019 and December 31, 2018	(708)	(708)
Accumulated deficit	(412,444)	(397,977)
Accumulated other comprehensive loss	2	(32)
Total Caladrius Biosciences, Inc. stockholders' equity	25,248	37,726
Noncontrolling interests	(266)	(272)
Total stockholders' equity	24,982	37,454
Liabilities and Equity, Total	$ 31,671	$ 44,580